ADI-001 Highly Effective, Safe for Heavily Pretreated NHL in Preliminary Phase 1 Data

Article

ADI-001 does not require genetic engineering to remove TCRs to avoid GvHD, making them ideal for an off-the-shelf cell therapy.

The novel, off-the-shelf CD20 CAR-modified gamma and delta T cell therapy ADI-001 demonstrated a promising early objective response rate (ORR) of 75% with a favorable safety profile for heavily pretreated patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL), according to a statement from Adicet Bio, the company developing the therapy.1

These findings from the phase 1 study were announced separately from a presentation on the design of the study at the 2021 ASH Annual Meeting.2 There were 6 patients with heavily pretreated R/R NHL enrolled at the time of the November 22, 2021, analysis, with 4 evaluable for efficacy. The ORR consisted of 2 complete responses (CR) and 1 partial response (PR) and at the time of the assessment there were no ADI-001-related serious adverse events reported, including a lack of graft-vs-host disease (GvHD), neurotoxicity, and high-grade cytokine release syndrome, which are common with other CAR T-cell therapies.

“The unequivocal responses to ADI-001 in this heavily pretreated patient population at such low dose levels are highly promising,” lead investigator Sattva Neelapu, MD, professor in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, said in a statement. “These data suggest that ADI-001 has the potential to be an effective treatment option for B cell malignancies if confirmed in further clinical testing. ADI-001 does not require gene editing and provides complementary innate, adaptive, and CAR-mediated antitumor effects which may improve durability and minimize emergence of tumor resistance.”

For ADI-001, cells are collected from a qualified donor and an antibody, AM3529, is used to isolate and activate the gamma delta T cells, which have HLA independent T cell receptors (TCR) and are unlikely to cause GvHD. As a result of the intrinsic benefits of these cells, ADI-001 does not require genetic engineering to remove TCRs to avoid GvHD, making them ideal for an off-the-shelf cell therapy. For ADI-001, once the gamma delta T cells are isolated, they are next transduced with a second-generation CAR specific to CD20 and store until administration. The construct has 4-1BB and CD3 zeta signaling domains.

“Gamma delta T cells have many potential advantages over conventional alpha beta T cells used for CAR T cell therapies,” Neelapu said during a presentation of the study's design at ASH. “They can impart both innate and adaptive immunity via the T cell and NK receptors on the cell surface. They have intrinsic antitumor activity that is MHC-independent, they are not expected to cause graft-vs-host disease, and they do not require T cell receptor editing.”

For the ongoing study (NCT04735471), patients are first administered a lymphodepleting regimen of fludarabine (30 mg/m2 per day for 3 days) and cyclophosphamide (500 mg/m2 per day for 3 days) 5 days prior to a one-time infusion of ADI-001. The protocol allows for optional pretreatment with ADI-001 following a response and safety assessment at 28 days.

The ongoing study consists of a dose escalation portion exploring 3 dose levels, starting at 30 million CAR+ cells, followed by 100 million, and finally 300 million CAR+ cells. The study plans to enroll 30 patients with R/R B cell NHL for the dose escalation portion of the study. In part 2, approximately 36 patients will be enrolled into 3 separate cohorts stratified by disease, with cohorts for diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, and other subtypes of NHL. A third part of the study will explore the addition of low-dose subcutaneous IL-2 to ADI-001. This part of the study seeks to enroll 12 patients. Part 2 and 3 will utilize the maximum tolerated dose (MRD) of ADI-001 identified in part 1 of the study.

All patients enrolled in the study had at least 2 prior regimens, including treatment with an anti-CD20 antibody. ECOG performance status was either 0 or 1 and all patients are required to have adequate hematologic and organ function. Those with CD20-negative disease are excluded from the study and patients can receive a prior anti-CD19 CAR T-cell therapy but it must have been received more than 6 weeks prior to study entry.

For the early efficacy analysis announced ahead of ASH, evaluable patients had received a median of 5 prior regimens. Three of the 4 patients received the lowest dose level (30 million cells) and 1 received the second dose level (100 million cells) in part 1 of the study. At the lowest dose, there was 1 CR and 1 PR, which was a near CR. The single patient evaluable at the second dose had achieved a CR. One of the patients who experienced a CR had received a prior autologous CD19-directed CAR T-cell therapy. This patient had DLBCL.

In these 4 patients, there was a significant increase in circulating IL-15 following lymphodepletion and ADI-001 expansion and proliferation was noted by quantitative polymerase chain reaction and by flow cytometry. IL-2 and IL-8 were observed in the first 14 days following administration of ADI-001, which is an indication of ADI-001 activation. There were no meaningful IL-6 increases seen following ADI-001 treatment, except for 1 patient who developed a COVID-19 infection.

The primary end point of part 1 of the study is the incidence of dose limiting toxicities and discovery of the MTD, Neelapu noted. For part 2 and 3, the safety and efficacy of the MTD or maximum administered dose of ADI-001 will be further explored. Secondary objectives will examine pharmacokinetics, immunogenicity, and antitumor activity. The study is currently enrolling at 5 different sites in the United States.

For more coverage of ASH 2021, click here.

REFERENCES
1. Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell Therapy. News release. Adicet Bio. December 6, 2021. https://investor.adicetbio.com/news-releases/news-release-details/adicet-bio-announces-positive-interim-clinical-data-first-ever
2. Neelapu SS, Hamadani M, Stevens D, et al. A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-Engineered Allogeneic Gamma Delta (γδ) T Cells in Adults with B Cell Malignancies, in Monotherapy and Combination with IL-2. Presented at: 2021 ASH Annual Meeting and Exposition; December 11-14, 2021; Atlanta, GA. Abstract 2834
Related Videos
Paula Cannon, PhD, the president elect of ASGCT and a distinguished professor of microbiology at Keck School of Medicine of USC
George Tachas, PhD
Alexandra Gomez-Arteaga, MD
Pietro Genovese, PhD, the principal investigator at the Gene Therapy Program of Dana-Farber/Boston Children’s Cancer and Blood Disorder Center
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
© 2024 MJH Life Sciences

All rights reserved.